- Home
- INVE vs VRCA Comparison
INVE vs VRCA Comparison
Compare INVE & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVE | VRCA |
|---|---|---|
| Founded | 1990 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.8M | 87.5M |
| IPO Year | 1997 | 2018 |
Fundamental Metrics
Financial Performance| Metric | INVE | VRCA |
|---|---|---|
| Price | $3.71 | $5.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $5.50 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 134.5K | 113.7K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $60,219,000.00 | $35,577,000.00 |
| Revenue This Year | $19.09 | N/A |
| Revenue Next Year | $20.40 | $92.12 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 7.21 | ★ 370.22 |
| 52 Week Low | $2.98 | $0.39 |
| 52 Week High | $4.08 | $9.82 |
Technical Indicators
Market Signals| Indicator | INVE | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 56.12 | 54.14 |
| Support Level | $3.23 | $5.18 |
| Resistance Level | $3.76 | $6.48 |
| Average True Range (ATR) | 0.23 | 0.52 |
| MACD | 0.02 | 0.13 |
| Stochastic Oscillator | 57.14 | 72.66 |
Price Performance
Historical ComparisonAbout INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.